Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.
There are two subsets of Hematopoietic stem cells (HSC); one subset that provides balanced production of myeloid and lymphoid cells, and another that is biased toward production of the myeloid lineage.
Stanford scientists have developed a strategy that enables simultaneous and combinatorial genetic screening across different types of genetic perturbations (gene knockouts, knock-ins, overexpression, and gene domain modification).
Stanford scientists have discovered that bispecific antibodies can selectively bind cancer cells and block the CD47-SIRPα "don't eat me signal" to efficiently clear tumors with negligible toxicity.
Researchers at Stanford have harnessed nanoprobes to longitudinally track immune system activation at a single-cell level, in response to immunotherapies.
Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Mucins are known to be involved in tumor-progressive pathways but are difficult to target using small molecules and antibodies.
Cancers including breast, lung, colon and prostate account for almost ten million deaths worldwide every year. The main cause of cancer deaths is metastasis, which is the propensity of cancer cells to spread throughout the body.